✨ Free AI Report
Clene Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Clene Inc.
Company Research

Clene Inc.: Business Overview, Financials & Competitive Analysis

Clene Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with platform-eligible nanotech approach to mitochondrial disorders; value contingent on Phase 3 data and capital efficiency. Clene is advancing clinical-stage neurodegenerative therapies with a differentiated nanotech platform and experienced management, but faces execution risks inherent to clinical-stage biotech. Lead asset CNM-Au8 has completed multiple Phase 2 trials, yet.

What is Clene Inc.'s industry? Clene Inc. (clene.com) operates in Neurology Drugs. AskCyborg classifies Clene Inc. under Neurology Drugs in its company registry.

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Pa...

4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with platform-eligible nanotech approach to mitochondrial disorders; value contingent on Phase 3 data and...

Read the full analyst-debate transcript →
Industry Neurology Drugs
5 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Clene Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Clene Inc.

AskCyborg analysts argue the bull and bear cases for Clene Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Clene Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Clene Inc. Overview

Pro stress-test →

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis, specializing in clean-surfaced nanotechnology (CSN) therapeutics. The company is advancing proprietary nanocrystal-based therapies targeting cellular energy dysfunction.

Strategic Profile

Pro stress-test →

The lead candidate CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism targeting mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. The company also develops CNM-ZnAg and CNM-AgZn17, silver and zinc-based agents for infectious disease and wound healing applications.

Competitive Landscape

Pro stress-test →

Clene competes in the neurodegenerative therapeutics space against established biotech players developing disease-modifying treatments for ALS, Parkinson's, and MS. Competitors include Denali Therapeutics, Neuralstem, and broader rare disease biotech firms. Clene's differentiation lies in its clean-surfaced nanotechnology platform targeting mitochondrial dysfunction, a mechanism distinct from traditional small-molecule or antibody approaches.

Industry Context

Clene Inc. operates in Neurology Drugs.

Key facts

Founded: 2012 · Headquarters: Salt Lake City, US · Revenue: Estimated $0–$5M (pre-revenue clinical-stage company)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Clene Inc..

  • CNM-Au8 has completed Phase 2 platform and proof-of-concept trials in ALS patients, plus Phase 2 trials in visual pathway deficits, multiple sclerosis remyelination, and Parkinson's disease. Advancement trajectory suggests multi-indication potential but no Phase 3 initiation confirmed as of September 2026.
  • As of Q1 2026, 72 institutions held shares representing approximately 17.18% of total shares with combined market value of 2.19M. Limited institutional conviction and modest market cap suggest capital raise risk ahead of Phase 3.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2026Management presentation at Emerging Growth Conference
Get alerted when Clene Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Denali TherapeuticsDeveloping disease-modifying therapies for neurodegenerative diseases→AlkermesClinical-stage biotech developing therapies for neurodegenerative and neurological disorders→Calithera BiosciencesBiopharmaceutical company developing therapeutics for metabolism-linked diseases including neurodegeneration→Voyager TherapeuticsGene therapy company developing treatments for neurodegenerative diseases including Parkinson's→Minerva NeurosciencesClinical-stage biotech developing novel therapeutics for neurological and psychiatric disorders→

Compare Clene Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Clene Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Clene Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Clene Inc. and its top competitor on Cyborg Score”
“What did Clene Inc. do this quarter?”
“Is Clene Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Clene Inc. do?+
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Pa...
What is Clene Inc.'s Cyborg Score?+
Clene Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Clene Inc.'s main competitors?+
Named competitors include Denali Therapeutics, Alkermes, Calithera Biosciences, Voyager Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Clene Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Clene Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Clene Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Neurology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Alkermes plc